Bio Techne Corp Stock Performance
| TECH Stock | USD 65.28 2.25 3.57% |
Bio Techne has a performance score of 5 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.44, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bio Techne will likely underperform. Bio Techne Corp right now shows a risk of 2.1%. Please confirm Bio Techne Corp expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Bio Techne Corp will be following its price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bio Techne Corp are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak fundamental indicators, Bio Techne may actually be approaching a critical reversion point that can send shares even higher in February 2026. ...more
Actual Historical Performance (%)
One Day Return 5.67 | Five Day Return 6.76 | Year To Date Return 5.67 | Ten Year Return 186.63 | All Time Return 57.5 K |
Forward Dividend Yield 0.0054 | Payout Ratio | Last Split Factor 4:1 | Forward Dividend Rate 0.32 | Dividend Date 2025-11-28 |
1 | Why Bio-Techne Stock Is Up Today | 10/31/2025 |
2 | Techne Fiscal Q1 Earnings Snapshot | 11/05/2025 |
3 | Bio-Techne Corp TECH Shares Purchased by Dorsey Whitney Trust CO LLC | 11/17/2025 |
| Bio Techne dividend paid on 28th of November 2025 | 11/28/2025 |
5 | Rhumbline Advisers Has 15.16 Million Stock Holdings in Bio-Techne Corp TECH - MarketBeat | 12/01/2025 |
6 | Russell Investments Group Ltd. Has 7.35 Million Position in Bio-Techne Corp TECH | 12/04/2025 |
7 | Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein Analysis | 12/09/2025 |
8 | Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology | 12/11/2025 |
9 | Corient Private Wealth LLC Reduces Stake in Bio-Techne Corp TECH - MarketBeat | 12/18/2025 |
| Begin Period Cash Flow | 151.8 M | |
| Total Cashflows From Investing Activities | -35.2 M |
Bio Techne Relative Risk vs. Return Landscape
If you would invest 6,048 in Bio Techne Corp on October 8, 2025 and sell it today you would earn a total of 480.00 from holding Bio Techne Corp or generate 7.94% return on investment over 90 days. Bio Techne Corp is currently generating 0.1447% in daily expected returns and assumes 2.0963% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Bio, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bio Techne Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio Techne's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bio Techne Corp, and traders can use it to determine the average amount a Bio Techne's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.069
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | TECH | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Bio Techne is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio Techne by adding it to a well-diversified portfolio.
Bio Techne Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Techne, and Bio Techne fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
| Return On Equity | 0.038 | ||||
| Return On Asset | 0.0625 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 9.54 B | ||||
| Shares Outstanding | 155.81 M | ||||
| Price To Earning | 74.38 X | ||||
| Price To Book | 4.73 X | ||||
| Price To Sales | 7.64 X | ||||
| Revenue | 1.22 B | ||||
| Gross Profit | 813.2 M | ||||
| EBITDA | 216.88 M | ||||
| Net Income | 73.4 M | ||||
| Cash And Equivalents | 247.03 M | ||||
| Cash Per Share | 6.30 X | ||||
| Total Debt | 444.06 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.44 X | ||||
| Book Value Per Share | 12.62 X | ||||
| Cash Flow From Operations | 287.56 M | ||||
| Earnings Per Share | 0.49 X | ||||
| Market Capitalization | 9.29 B | ||||
| Total Asset | 2.56 B | ||||
| Retained Earnings | 1.07 B | ||||
| Working Capital | 432.45 M | ||||
| Current Asset | 253.89 M | ||||
| Current Liabilities | 54.15 M | ||||
About Bio Techne Performance
By evaluating Bio Techne's fundamental ratios, stakeholders can gain valuable insights into Bio Techne's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bio Techne has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bio Techne has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 144.94 | 86.64 | |
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.05 | 0.05 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.04 | 0.04 |
Things to note about Bio Techne Corp performance evaluation
Checking the ongoing alerts about Bio Techne for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio Techne Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 100.0% of the company shares are owned by institutional investors | |
| On 28th of November 2025 Bio Techne paid $ 0.08 per share dividend to its current shareholders | |
| Latest headline from news.google.com: Corient Private Wealth LLC Reduces Stake in Bio-Techne Corp TECH - MarketBeat |
- Analyzing Bio Techne's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Techne's stock is overvalued or undervalued compared to its peers.
- Examining Bio Techne's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio Techne's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Techne's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio Techne's stock. These opinions can provide insight into Bio Techne's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bio Stock analysis
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |